1. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin;Hsiang;Cancer Res.,1989
2. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin;Hsiang;Cancer Res.,1988
3. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues;Hsiang;Cancer Res.,1989
4. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11;Kawato;Cancer Res.,1991
5. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors;Drengler;J. Clin. Oncol.,1999